68Ga-labeled radiopharmaceuticals for positron emission tomography

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 4, 2010, Pages 233-240

  Shetty, Dinesh ^a   Lee, Yun Sang ^a   Jeong, Jae Min ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

BAPEN; DOTA; Ga 68; Gallium 68; MSA; NOTA; Peptide; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOPEPTIN; DIAGNOSTIC AGENT; DISOPYRAMIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM 1,4,7 TRIAZACYCLONONANETRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID GA 68; GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1,4,8,11 TETRAAZACYCLOTETRADECANETETRAACETIC ACID GA 68; GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DISOPYRAMIDE GA 68; GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] GA 68; GALLIUM 68; GALLIUM DESFERRIOXAMINE OCTREOTIDE GA 68; GALLIUM TRIS(4,6 DIMETHOXYSALICYLALDIMINE) N,N' BIS(3 AMINOPROPYL) N,N' ETHYLENEDIAMINE GA 68; INDIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MELANOCYTE STIMULATING HORMONE IN 111; OCTREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG STRUCTURE; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS;

EID: 79952735576     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0056-6     Document Type: Review

References (63)

1. 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging. 2007;34:978-81.
2. Ehrhardt GJ, Welch MJ. A new germanium-63/gallium-68 generator. J Nucl Med. 1978;19:925-9.
3. 68Ga for medical application. J Nucl Med. 2007;48:1741-8.
4. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-93.
5. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-26.
6. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
7. 68Ga-DOTA-NOC and 18FDOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-8.
8. Parker D. Tumour targeting with radiolabelled macrocycle-antibody conjugates. Chem Soc Rev. 1990;19:271-91.
9. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry. 1983;22:292-9.
10. Chong HS, Ma X, Le T, Kwamena B, Milenic DE, Brady ED, et al. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J Med Chem. 2008;51:118-25.
11. Chong HS, Song HA, Ma X, Milenic DE, Brady ED, Lim S, et al. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. Bioconjug Chem. 2008;19:1439-47.
12. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005;32:287-92.
13. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830-6.
14. Sabatino G, Chinol M, Paganelli G, Papi S, Chelli M, Leone G, et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem. 2003;46:3170-3.
15. Tanaka K, Masuyama T, Hasegawa K, Tahara T, Mizuma H, Wada Y, et al. A submicrogram-scale protocol for biomolecule-based pet imaging by rapid 6p-azaelectrocyclization: visualization of sialic acid dependent circulatory residence of glycoproteins. Angew Chem Int Ed. 2008;47:102-5.
16. Tsang BW, Mathias CJ, Fanwick PE, Green MA. Structuredistribution relationships for metal-labeled myocardial imaging agents: comparison of a series of cationic gallium (III) complexes with hexadentate bis(salicylaldimine) ligands. J Med Chem. 1994;37:4400-6.
17. 68Ga[(4, 6-MeO2sal) 2BAPEN]+. J Nucl Med. 1993;34:1127-31.
18. Kung HF, Liu BL, Mankoff D, Kung MP, Billings JJ, Francesconi L, et al. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH. J Nucl Med. 1990;31:1635-40.
19. Fichna J, Janecka A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug Chem. 2003;14:3-17.
20. Janoki G, Harwig J, Chanachai W, Wolf W. 67Ga desferrioxamine-HSA: synthesis of chelon protein conjugates using carbodiimide as a coupling agent. Int J Appl Radiat Isot. 1983;34:871-7.
21. 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method. J Immunol Methods. 1987;104:93-102.
22. Mathias CJ, Sun YZ, Welch MJ, Connett JM, Philpott GW, Martell AE. N, N'-bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2-ethylenediamine-N, N'-diacetic acid: a new bifunctional chelate for radiolabeling antibodies. Bioconjug Chem. 1990;1:204-11.
23. Broan C, Cox J, Craig A, Kataky R, Parker D, Harrison A, et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J Chem Soc Perkin Trans. 1991;2:87-99.
24. 111In-labeled DTPA-peptide conjugates. Bioconjug Chem. 2001;12:630-4.
25. Chong HS, Garmestani K, Ma D, Milenic DE, Overstreet T, Brechbiel MW. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J Med Chem. 2002;45:3458-64.
26. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med. 1997;70:471-9.
27. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:63-70.
28. Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol. 1999;10:S17-21.
29. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-82.
30. 111In-DTPAoctreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999;40:762-7.
31. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-47.
32. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med. 1994;35:317-25.
33. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421-9.
34. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S-6S.
35. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.
36. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-47.
37. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL, et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocytestimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945-53.
38. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alphamelanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116-23.
39. van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med. 1996;23:1508-13.
40. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134-9.
41. Behr TM, Behe MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109.
42. 125I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8:1139-46.
43. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198-208.
44. 68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging. 2008;35:352-64.
45. 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging. 2005;32:1259-68.
46. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004;45:347-55.
47. Clarke ET, Martell AE. Stabilities of the Fe(Iii), Ga(Iii) and in(Iii) chelates of N, N', N"-triazacyclononanetriacetic acid. Inorg Chim Acta. 1991;181:273-80.
48. Clarke ET, Martell AE. Potentiometric and spectrophotometric determination of the stabilities of in(Iii), Ga(Iii) and Fe(Iii) complexes of N, N', N"-tris(3,5-dimethyl-2-hydroxybenzyl)-1,4,7-triazacyclononane. Inorg Chim Acta. 1991;186:103-11.
49. Clarke ET, Martell AE. Stabilities of trivalent metal-ion complexes of the tetraacetate derivatives of 12-membered, 13-membered and 14-membered tetraazamacrocycles. Inorg Chim Acta. 1991;190:37-46.
50. Shetty D, Jeong JM, Hoigebazar L, Lee YS, Lee DS, Chung JK, et al. (2010) Formation and characterization of gallium(III) complexes with monoamide derivatives of 1,4,7-triazacyclononane-1,4,7-triacetic acid: a pH dependant structural study. Eur J Inorg Chem 2010:In press.
51. Shetty D, Ju CH, Kim YJ, Lee JY, Lee YS, Lee DS, et al. (2010) Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography. Bioorg Med Chem 18. doi:10.1016/j.bmc. 2010.09.022.
52. 68Ga labeled amino acid derivatives for positron emission tomography of cancer cells. Nucl Med Biol 37. doi:10.1016/j.nucmedbio.2010.06.003.
53. Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radiol. 2006;13:598-609.
54. 68Ga-labeling and testing in tumor xenografted mice. J Med Chem. 2010;53:6378-85.
55. 68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med. 2005;46:354-64.
56. 68Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol 37. doi:10.1016/j.nucmedbio. 2010.09.010.
57. 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol. 2009;37:149-55.
58. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-7.
59. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-6.
60. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-8.
61. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359-63.
62. 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging. 2006;33:506.
63. 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763-9.